14/09/2017 - 05:37

PharmAust secures key European anti-cancer patent

14/09/2017 - 05:37


Upgrade your subscription to use this feature.

ASX-listed biotech PharmAust has been granted a core patent in Europe relating to the use of “aminoacetonitrile derivatives” as potent kinase inhibitors for the treatment of cancer. The patent is another positive step for Perth-based company in shoring up its global IP protections. It follows the granting of similar patents in key markets including the US, Australia and China.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options